The main objective of chronic hepatitis C virus (HCV) management is to provide high viral eradication rates with acceptable toxicity. The new era of direct-acting antivirals (DAAs) has considerably changed the standard of care, and each main congress provides new and insightful information. Very encouraging clinical data on interferon and ribavirin-free combinations with oral DAAs were recently made available, and comprise over 90%, and up to 100%, of infection cure rates for treatment-naïve patients; consistent results can also be observed across many difficult-to-cure subpopulations such as patients with advanced liver disease, HIV-coinfected patients, and patients in the post-liver transplant setting, which could, therefore, no longer be considered as difficult-to-cure populations. This review will summarise the highlights of the 2014 International Liver Congress that took place from 9th-13th April in London, UK, and will provide an outlook on the future of HCV treatment.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given